Insight and suicidality in psychosis: A cross-sectional study
Por:
Massons C., Lopez-Morinigo J.-D., Pousa E., Ruiz A., Ochoa S., Usall J., Nieto L., Cobo J., David A.S., Dutta R.
Publicada:
1 ene 2017
Resumen:
Aims We aimed to test whether specific insight dimensions are associated with suicidality in patients with psychotic disorders. Methods 143 patients with schizophrenia spectrum disorders were recruited. Suicidality was assessed by item 8 of the Calgary Depression Scale for Schizophrenia (CDSS). Insight was measured by the Scale of Unawareness of Mental Disorder (SUMD) and the Markova and Berrios Insight Scale. Bivariate analyses and multivariable logistic regression models were conducted. Results Those subjects aware of having a mental illness and its social consequences had higher scores on suicidality than those with poor insight. Awareness of the need for treatment was not linked with suicidality. The Markova and Berrios Insight scale total score and two specific domains (awareness of “disturbed thinking and loss of control over the situation” and “having a vague feeling that something is wrong”) were related to suicidality. However, no insight dimensions survived the multivariable regression model, which found depression and previous suicidal behaviour to predict suicidality. Conclusions Suicidality in psychosis was linked with some insight dimensions: awareness of mental illness and awareness of social consequences, but not compliance. Depression and previous suicidal behaviour mediated the associations with insight; thus, predicting suicidality. © 2017
Filiaciones:
Massons C.:
Mental Health Deparment, Corporació Sanitària Parc Taulí- Universitat Autònoma de Barcelona, Campus d'Excel·lència Internacional, Bellaterra, 08193, Spain
Lopez-Morinigo J.-D.:
King's College of London, Institute of Psychiatry, Psychology and Neurosciences, Department of Psychosis Studies, London, United Kingdom
Pousa E.:
Mental Health Deparment, Corporació Sanitària Parc Taulí- Universitat Autònoma de Barcelona, Campus d'Excel·lència Internacional, Bellaterra, 08193, Spain
Ruiz A.:
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain
IMIM ( Hospital del Mar Medical Research Institute), Barcelona, Spain
Ochoa S.:
Research and Development Unit, Parc Sanitari San Joan de Dèu – CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain
Usall J.:
Research and Development Unit, Parc Sanitari San Joan de Dèu – CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain
Nieto L.:
Department of Research Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calzada México-Xochimilco 101, San Lorenzo Huipulco, Tlalpan, México D.F, 14370, Mexico
Cobo J.:
Mental Health Deparment, Corporació Sanitària Parc Taulí- Universitat Autònoma de Barcelona, Campus d'Excel·lència Internacional, Bellaterra, 08193, Spain
Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain
Centro de Investigación Biomédica En Red de Salud Mental, CIBERSAM, Sabadell, Spain
David A.S.:
King's College of London, Institute of Psychiatry, Psychology and Neurosciences, Department of Psychosis Studies, London, United Kingdom
Dutta R.:
King's College London, Institute of Psychiatry, Psychology and Neurosciences, Department of Psychological Medicine, London, United Kingdom
|